H.R. 8005House119th Congress (2025-2027)Passed House

Stop Pills That Kill Act

Sponsored by Gabe EvansRep. Gabe Evans (R-CO)
Introduced March 19, 2026

AI-Generated Summary

Updated September 22, 2026 at 5:44 AM UTC

The Stop Pills That Kill Act amends the Controlled Substances Act to treat tablet‑making and capsule‑making machines, and key parts of those machines, like punches and dies, as regulated items. It requires permanent serial numbers on such equipment, expands who is considered a “regulated person,” and makes it illegal to tamper with those numbers. The bill also adds penalties for manufacturing or distributing these machines when they are intended for illicit drug production, defines counterfeit pills that contain fentanyl‑type or other synthetic opioids, and orders the DEA to create a plan and yearly reports on counterfeit‑pill threats.

Key Provisions

  • Defines manufacturers, distributors, importers, exporters, brokers, and traders of tableting/encapsulating machines and critical parts as regulated persons.
  • Mandates that each machine or critical part have a permanent, engraved serial number and that transactions be recorded with that number.
  • Prohibits removing, altering, or selling machines with tampered serial numbers, with criminal penalties including fines and up to 20 years in prison for serious violations.
  • Requires the Attorney General to issue regulations on these requirements within 180 days, covering both new and existing equipment.
  • Creates extraterritorial jurisdiction for making or distributing machines intended for illegal drug manufacturing or unlawful import into the U.S., with tiered prison terms up to 20 years.
  • Defines “counterfeit pill containing an illicit synthetic substance” to include fentanyl, its analogues, and other synthetic opioids, and adds them to prohibited substances.
  • Orders the DEA to develop an operation and response plan for counterfeit synthetic‑drug pills within 180 days and to submit annual reports to Congress through FY 2031.

Legislative Activity

Stay on top of the latest movement without scrolling through every action

15 earlier actions
SenateIntro Referral Latest Action

Received in the Senate and Read twice and referred to the Committee on the Judiciary.

September 16, 2026

View full timeline
HouseIntro Referral

Introduced in House

March 19, 2026

HouseIntro Referral

Referred to the Committee on the Judiciary, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

March 19, 2026

HouseCommittee

Referred to the Subcommittee on Health.

March 19, 2026

HouseCommittee

Subcommittee Consideration and Mark-up Session Held

July 15, 2026

HouseCommittee

Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote.

July 15, 2026

HouseCommittee

Committee Consideration and Mark-up Session Held

July 20, 2026

HouseCommittee

Committee Consideration and Mark-up Session Held

July 21, 2026

HouseCommittee

Ordered to be Reported in the Nature of a Substitute by the Yeas and Nays: 43 - 6.

July 21, 2026

HouseFloor

Mr. Guthrie moved to suspend the rules and pass the bill, as amended.

September 15, 2026 • 7:31 PM

HouseFloor

Considered under suspension of the rules. (consideration: CR H5674-5676)

September 15, 2026 • 7:31 PM

HouseFloor

DEBATE - The House proceeded with forty minutes of debate on H.R. 8005.

September 15, 2026 • 7:31 PM

HouseFloor

Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

September 15, 2026 • 7:38 PM

HouseFloor

On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5674-5675)

September 15, 2026 • 7:38 PM

HouseFloor

Motion to reconsider laid on the table Agreed to without objection.

September 15, 2026 • 7:38 PM

HouseFloor

The title of the measure was amended. Agreed to without objection.

September 15, 2026 • 7:38 PM

SenateIntro Referral

Received in the Senate and Read twice and referred to the Committee on the Judiciary.

September 16, 2026

Floor Debate

3 members

What members said about H.R. 8005 on the floor

2 Republicans1 Democrat
Gabe Evans
Rep. Gabe EvansR-CO-8 · Sep 15, 2026

Mr. Speaker, I thank the gentleman from Kentucky for yielding. Mr. Speaker, I am proud to rise today in strong support of my bill to help combat the epidemic of fentanyl deaths that have been driven…

Lizzie Fletcher
Rep. Lizzie FletcherD-TX-7 · Sep 15, 2026

Mr. Speaker, I yield myself such time as I may consume. Mr. Speaker, I rise in support of H.R. 8005. This legislation addresses the supply chains that turn illicit chemicals into counterfeit pills by…

Brett Guthrie
Rep. Brett GuthrieR-KY-2 · Sep 15, 2026

Mr. Speaker, I move to suspend the rules and pass the bill (H.R. 8005) to amend the Controlled Substances Act to prohibit certain acts related to fentanyl, analogues of fentanyl, and counterfeit…

Bill Text

3 versions available

Reading Mode
Latest
Referred in SenateIssued September 16, 2026

IIB

119th CONGRESS

2d Session

H. R. 8005

IN THE SENATE OF THE UNITED STATES

September 16, 2026

Received; read twice and referred to the Committee on the Judiciary

AN ACT

To amend the Controlled Substances Act to prevent the misuse of a tableting machine, encapsulating machine, or critical part of a tableting and encapsulating machine for the illicit manufacture of a controlled substance or listed chemical, and for other purposes.

1.

Short title

This Act may be cited as the Stop Pills That Kill Act.

2.

Regulation of certain machines

(a)

Definitions

Section 102 of the Controlled Substances Act (21 U.S.C. 802) is amended—

(1)

by striking paragraph (38) and inserting the following:

(38)

The term regulated person means a person who—

(A)

manufactures, distributes, imports, or exports a listed chemical;

(B)

manufactures, distributes, delivers, sells, imports, or exports a tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine; or

(C)

acts as a broker or trader for a regulated transaction involving a listed chemical, tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine.

;

(2)

by striking paragraph (39)(B) and inserting the following:

(B)

a distribution, delivery, sale, importation, exportation, or international transaction of a tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine.

;

(3)

in paragraph (42), by inserting , tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine after listed chemical;

(4)

in paragraph (43), in the matter preceding subparagraph (A)—

(A)

by striking an international and inserting a regulated; and

(B)

by inserting , tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine after listed chemical; and

(5)

by adding at the end the following:

(61)

The term critical part, when used in reference to a tableting or encapsulating machine, means any of the following integral parts of a tableting or encapsulating machine:

(A)

An upper punch.

(B)

A lower punch.

(C)

A die.

(D)

Any additional parts that the Attorney General has determined to be integral to the operation of a tableting or encapsulating machine, provided that such determination—

(i)

is made through rulemaking; and

(ii)

does not go into effect until the rulemaking process has been completed.

(62)

The term die means a tool that serves as the mold in which a product is compressed to form the desired size and shape of a tablet or capsule.

(63)

The term lower punch means the punch inserted into the turret below the die.

(64)

The term punch means a rod-shaped tool used in producing tablets and other products.

(65)

The term upper punch means the punch inserted into the turret above the die.

.

(b)

Regulation

(1)

Records of regulated transactions

Section 310(a) of the Controlled Substances Act (21 U.S.C. 830(a)) is amended—

(A)

in paragraph (1), by striking or an encapsulating machine and inserting , encapsulating machine, or critical part of a tableting or encapsulating machine; and

(B)

in paragraph (2)—

(i)

by striking or encapsulating machine and inserting , encapsulating machine, or critical part of a tableting or encapsulating machine; and

(ii)

by inserting before the period at the end the following: and shall identify the tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine by means of a serial number that is engraved, cast, or otherwise permanently affixed to a nonremovable part of the tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine.

(2)

Reports to attorney general

Section 310(b)(1) of the Controlled Substances Act (21 U.S.C. 830(b)(1)) is amended by striking subparagraph (D) and inserting the following:

(D)

any regulated transaction in a tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine, including the serial number affixed to the tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine.

.

(3)

Regulations

(A)

In general

Not later than 180 days after the date of enactment of this Act, the Attorney General shall promulgate regulations carrying out the amendments made by paragraphs (1) and (2).

(B)

Inclusion

The regulations required under subparagraph (A) shall include requirements regarding serial numbers affixed to tableting machines, encapsulating machines, or critical parts of tableting or encapsulating machines manufactured on or before the date of enactment of this Act.

(4)

Applicability

(A)

In general

Except as specified in subparagraph (B), the amendments made by paragraphs (1) and (2) shall apply only to any tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine manufactured, distributed, delivered, sold, imported, exported, or included in an international transaction after the effective date of the regulations promulgated under paragraph (3).

(B)

Exception

Beginning on the date that is 180 days after the date of the enactment of this Act, the amendments made by paragraph (1) of this subsection to paragraphs (1) and (2) of section 310(a) of the Controlled Substances Act (21 U.S.C. 830(a)) shall apply with respect to a tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine manufactured on or before the date of enactment of this Act.

(c)

Prohibited acts

Section 403(a) of the Controlled Substances Act (21 U.S.C. 843(a)) is amended—

(1)

in paragraph (8), by striking or at the end;

(2)

in paragraph (9), by striking the period at the end and inserting a semicolon; and

(3)

by adding at the end the following:

(10)

to remove, alter, or obliterate any serial number affixed to a tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine, that is required to have a serial number and with reasonable cause to believe the serial number is so required; or

(11)

to transport, ship, receive, possess, distribute, deliver, sell, import, or export a tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine that is required to have a serial number, knowing that the serial number has been removed, altered, or obliterated, and with reasonable cause to believe the serial number is so required.

.

3.

Providing for extraterritorial jurisdiction

(a)

Possession, manufacture, or distribution for purposes of unlawful importation

Section 1009 of the Controlled Substances Act (21 U.S.C. 959) is amended—

(1)

by redesignating subsections (c) and (d) as subsections (d) and (e), respectively;

(2)

by inserting after subsection (b) the following:

(c)

It shall be unlawful for any person to manufacture or distribute a tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine—

(1)

intending or knowing that the tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine will be used to illicitly manufacture a controlled substance or listed chemical; and

(2)

intending, knowing, or having reasonable cause to believe that the tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine will be unlawfully imported into the United States.

; and

(3)

in subsection (d), as so redesignated—

(A)

in paragraph (1), by striking or at the end;

(B)

in paragraph (2), by striking the period at the end and inserting ; or; and

(C)

by adding at the end the following:

(3)

manufacture or distribute a tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine—

(A)

intending or knowing that the tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine will be used to illicitly manufacture a controlled substance or listed chemical; and

(B)

intending, knowing, or having reasonable cause to believe that the tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine will be unlawfully imported into the United States.

.

(b)

Prohibited acts

Section 1010 of the Controlled Substances Act (21 U.S.C. 960) is amended—

(1)

in subsection (d)—

(A)

in paragraph (6), by striking or at the end;

(B)

in paragraph (7)—

(i)

by striking section 959 of this title and inserting section 1009; and

(ii)

by striking the period at the end and inserting ; or;

(C)

by inserting after paragraph (7) the following:

(8)

manufactures or distributes a tableting machine, encapsulating machine, or critical part of a tableting or encapsulating machine in violation of section 1009,

; and

(D)

in the matter following paragraph (8), as so inserted, by striking shall be fined and all that follows through or both and inserting the following: shall be fined in accordance with title 18, United States Code, imprisoned for the applicable period described in subsection (e), or both; and

(2)

by adding at the end the following:

(e)

The applicable period described in this subsection is the following:

(1)

In the case of a violation of paragraph (1) or (3) of subsection (d) involving a list I chemical, not more than 20 years.

(2)

Subject to paragraph (4), in the case of a violation of paragraph (7) of subsection (d), not more than 10 years.

(3)

Subject to paragraph (4), in the case of a violation of paragraph (8) of subsection (d), not more than 8 years.

(4)

In the case of a violation of paragraph (7) or (8) of subsection (d) that involves more than 1,000 kilograms of a chemical or product or more than 100 machines that are tableting machines or encapsulating machines, not more than 15 years.

(5)

In the case of any other violation of subsection (d), not more than 10 years.

.

(c)

United States Sentencing Commission

Pursuant to its authority under section 994(p) of title 28, United States Code, the United States Sentencing Commission shall review and amend the Federal sentencing guidelines and policy statements of the Commission in accordance with this Act and the amendments made by this Act.

4.

Counterfeit pills containing an illicit synthetic substance

(a)

Definition

In this Act, the term counterfeit pill containing an illicit synthetic substance means a substance in pill or tablet form that—

(1)

is a counterfeit substance, as defined in section 102(7) of the Controlled Substances Act (21 U.S.C. 802(7)); and

(2)

contains fentanyl, an analogue of fentanyl, a fentanyl-related substance, methamphetamine, an illicit depressant or stimulant substance, an illicit narcotic, or an illicit synthetic opioid.

(b)

Prohibited acts

Section 403(d)(2) of the Controlled Substances Act (21 U.S.C. 843(d)(2)) is amended, in the matter preceding subparagraph (A), by inserting , fentanyl, an analogue of fentanyl, or a fentanyl-related substance after methamphetamine.

(c)

Comprehensive plan

(1)

In general

Not later than 180 days after the date of enactment of this Act, the Administrator of the Drug Enforcement Administration shall establish and implement an operation and response plan to address counterfeit pills containing an illicit synthetic substance.

(2)

Contents

The plan required under paragraph (1) shall include—

(A)

strategies to enable and empower Federal law enforcement efforts to investigate and seize counterfeit pills containing an illicit synthetic substance;

(B)

specific ways that education and prevention efforts to stop the use of counterfeit pills containing an illicit synthetic substance will be increased, including—

(i)

how ongoing efforts, such as Operation Engage, are effective in increasing education and prevention; and

(ii)

how such ongoing efforts are tailored to youth and teen access; and

(C)

an audit of current campaigns on counterfeit pills containing an illicit synthetic substance, including a review of data and other available information on how the campaigns can be tailored, adjusted, or improved to better address the flow of such counterfeit pills.

(3)

Report to Congress

(A)

Report

Not later than 1 year after the date of enactment of this Act, and every year thereafter through fiscal year 2031, the Attorney General, in consultation with the Administrator of the Drug Enforcement Administration and the Director of the Office of National Drug Control Policy, shall submit to Congress a report containing information regarding the collection of counterfeit pills containing an illicit synthetic substance and prosecutions undertaken in connection with such counterfeit pills.

(B)

Contents

The report required under subparagraph (A) shall include the following:

(i)

Data on the aggregate number of counterfeit pills containing an illicit synthetic substance that have been seized and collected by Federal law enforcement agencies.

(ii)

A description of pharmaceutical markings used for counterfeit pills containing an illicit synthetic substance, including how the markings compare to required labeling for products approved by the Food and Drug Administration.

(iii)

A breakdown of which illicit substances are present in counterfeit pills containing an illicit synthetic substance.

(iv)

Data outlining the geographic origin and points of seizure of counterfeit pills containing an illicit synthetic substance.

(v)

Data on the charges filed pursuant to paragraph (1) or (2) of section 401(a) of the Controlled Substances Act (21 U.S.C. 841(a)) in relation to counterfeit pills containing an illicit synthetic substance, unless disclosure of the data would—

(I)

require unsealing an indictment; or

(II)

undermine investigations and charges brought by the Department of Justice.

(vi)

Data on the convictions and sentences against those who are found guilty under paragraph (1) or (2) of section 401(a) of the Controlled Substances Act (21 U.S.C. 841(a)) as it pertains to counterfeit pills containing an illicit synthetic substance.

(vii)

Any prevention measures that the Department of Justice, the Drug Enforcement Administration, or the Office of National Drug Control Policy are undertaking to limit and reduce the spread of counterfeit pills containing an illicit synthetic substance, including ongoing public awareness campaigns.

Passed the House of Representatives September 15, 2026.

Kevin F. McCumber,

Clerk.